October 30th, 2018 – Xstrahl Medical, global leaders in superficial radiotherapy devices and advanced radiation research systems, has appointed Neil Madle as Commercial Director - Radiotherapy. Based at Xstrahl’s UK head office in Surrey, Madle will be responsible for...
There have been a growing number of studies combining radiotherapy with immunotherapy to enhance both local and metastatic tumor cell kill leveraging the immune-mediated abscopal effect. This abscopal effect can enable the killing of metastatic cells, distant from the...
Low dose radiotherapy is being increasingly used to treat benign syndromes, however long term impact studies on these low dose radiotherapy treatments has long been neglected. In their paper “The Erlangen Dose Optimization trial for low-dose radiotherapy of benign...
Xstrahl has just returned from the 64th Annual Meeting of the Radiation Research Society in Chicago, which as usual featured some of the best of recent technology, papers and experts. We would like to thank everyone who came to our booth to see Xstrahl’s latest...
Only a few days are left before the ASTRO’s 60th annual meeting will open its doors to more than 10,000 radiation oncology and research professionals, providing an ideal platform to discuss and discover solutions to the most pressing issues and examine the latest...
As the population ages, more elderly patients require radiotherapy-based treatment for their pelvic malignancies, including muscle-invasive bladder cancer, as they are unfit for major surgery. Therefore, there is an urgent need to find radiosensitizing agents...
Less than one month is left before the beginning of the largest annual radiation oncology meeting; ASTRO 2018, which this year will be taking place on the 21st to 24th of October at the Henry B. Gonzalez Convention Center, in San Antonia, Texas. Xstrahl would like to...
According to the American Academy of Dermatology, it is estimated that non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million Americans a year and 178,560 new cases of melanoma, including 91,270 invasive, will...
Combined immune checkpoint blockade has led to rare autoimmune complications, such as fatal myocarditis. Recent approvals of several anti-programmed death 1 (anti-PD-1) drugs for lung cancer treatment prompted ongoing clinical trials that directly combine PD-1...
Contact Us